1. Home
  2. TNXP vs SQNS Comparison

TNXP vs SQNS Comparison

Compare TNXP & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • SQNS
  • Stock Information
  • Founded
  • TNXP 2007
  • SQNS 2003
  • Country
  • TNXP United States
  • SQNS France
  • Employees
  • TNXP N/A
  • SQNS N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • TNXP Health Care
  • SQNS Technology
  • Exchange
  • TNXP Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • TNXP 71.6M
  • SQNS 85.7M
  • IPO Year
  • TNXP N/A
  • SQNS 2011
  • Fundamental
  • Price
  • TNXP $18.18
  • SQNS $2.09
  • Analyst Decision
  • TNXP Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • TNXP 2
  • SQNS 1
  • Target Price
  • TNXP $585.00
  • SQNS $7.50
  • AVG Volume (30 Days)
  • TNXP 2.6M
  • SQNS 71.6K
  • Earning Date
  • TNXP 03-18-2025
  • SQNS 02-11-2025
  • Dividend Yield
  • TNXP N/A
  • SQNS N/A
  • EPS Growth
  • TNXP N/A
  • SQNS N/A
  • EPS
  • TNXP N/A
  • SQNS 2.00
  • Revenue
  • TNXP $10,094,000.00
  • SQNS $36,762,000.00
  • Revenue This Year
  • TNXP $84.08
  • SQNS N/A
  • Revenue Next Year
  • TNXP $126.94
  • SQNS $95.51
  • P/E Ratio
  • TNXP N/A
  • SQNS $1.04
  • Revenue Growth
  • TNXP 29.94
  • SQNS 9.36
  • 52 Week Low
  • TNXP $6.76
  • SQNS $0.85
  • 52 Week High
  • TNXP $672.00
  • SQNS $4.28
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 48.95
  • SQNS 32.91
  • Support Level
  • TNXP $12.80
  • SQNS $2.10
  • Resistance Level
  • TNXP $31.87
  • SQNS $2.49
  • Average True Range (ATR)
  • TNXP 4.30
  • SQNS 0.15
  • MACD
  • TNXP 0.57
  • SQNS 0.00
  • Stochastic Oscillator
  • TNXP 22.53
  • SQNS 14.89

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: